NRC Health (NRC) Análisis de acciones

Descripción de la empresa

National Research Corporation, operating under the ticker NRC, functions within the healthcare sector by delivering analytics and insights designed to measure and enhance the patient and employee experience for organizations across the United States. Specifically, the firm provides market experience solutions that facilitate a subscription-based approach to tracking awareness, perception, and other qualitative metrics essential for healthcare improvement. This entity is classified within the Health Information Services industry, a segment focused on the collection, processing, and dissemination of medical data to support operational efficiency and strategic decision-making. The company currently maintains a market capitalization of $387.60M and employs 357 individuals, generating annual revenue of $137.39M based on trailing twelve-month figures. These valuation metrics indicate that the market assigns a significant premium to the firm's intellectual property and recurring revenue model, positioning it as a mid-cap player with specialized capabilities rather than a broad-market utility. The revenue scale of approximately $137 million suggests the business has achieved a level of market penetration sufficient to sustain operations but remains sensitive to fluctuations in healthcare spending and client retention rates.

Salud financiera

The company reports a trailing twelve-month revenue of $137.39M, which resulted in a net income of $11.29M and an EBITDA of $37.00M for the same period. The substantial gap between the $137.39M revenue and the $11.29M net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of top-line growth, leaving a profit margin of 8.4%. Despite the lower net income relative to revenue, the EBITDA figure of $37.00M highlights a strong underlying operational cash generation capability before interest, taxes, depreciation, and amortization. The firm generated free cash flow of $16.65M, which indicates a degree of financial flexibility allowing for capital allocation toward technology upgrades or debt reduction without immediate reliance on external financing. However, the balance sheet presents a leveraged profile with total debt of $80.24M against cash holdings of only $4.14M, resulting in a debt-to-equity ratio of 573.55. This high leverage ratio suggests the company relies heavily on debt financing relative to its equity base, which increases financial risk during periods of rising interest rates or declining cash flows. Liquidity is constrained further by a current ratio of 0.55, indicating that current liabilities exceed current assets and implying potential short-term liquidity challenges if cash conversion cycles lengthen. Return on equity stands at 51.2% while return on assets is 13.7%, metrics that demonstrate management's effectiveness in generating returns from shareholders' capital and the company's total asset base respectively.

Evaluación de valoración

Valuation multiples for National Research Corporation show a trailing P/E ratio of 34.08 compared to a forward P/E of 14.69, a disparity that implies the market expects a significant turnaround in earnings performance to align current stock prices with future expectations. The price-to-book ratio is reported at 27.57, indicating that the market values the company at a substantial premium over its book value, likely reflecting the intangible nature of its intellectual property and recurring revenue streams. Alternative valuation metrics include a price-to-sales ratio of 2.82 and an EV/EBITDA of 12.53, which suggest the company is priced based on revenue growth potential and earnings power rather than pure asset backing. The stock has traded within a 52-week range bounded by a high of $22.79 and a low of $9.76, providing a historical context for price volatility and investor sentiment over the past year. The beta value of 0.41 indicates that the stock's price volatility is significantly lower than that of the broader market, suggesting it may act as a defensive position during periods of heightened market uncertainty.

Growth & Income

Recent financial performance data indicates a revenue growth rate of -4.6% year-over-year and an earnings growth rate of -74.4% year-over-year. The fact that earnings growth is declining at a much faster rate than revenue, which is itself contracting, implies that margins are under pressure or one-time charges have impacted the bottom line more severely than top-line sales. The company pays a dividend with a yield of 3.2%, yet the payout ratio stands at 104.0%, meaning the firm is distributing more in dividends than its current earnings generate. This payout ratio exceeding 100% suggests that the dividend may be partially funded by cash reserves or debt proceeds rather than operating earnings, which limits the sustainability of the current dividend level if earnings do not recover quickly. The overall growth and income profile currently reflects a company in a transitional phase where declining earnings growth and a non-sustainable dividend payout coexist with a low-beta, defensively structured balance sheet.